Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?

Reviewed 10 sourcesPublished by PepVault

Compounded semaglutide and tirzepatide are not FDA-approved. What compounding is, what the FDA decided and when, and how a vial differs from a brand pen.

A man in a navy quarter-zip carrying a tote of greens and a baguette down a brick street
Last reviewed
Sources
10
Questions
8
Compounds
2

The short answer

No. A compounded version can carry the same active ingredient, but it is not FDA-approved and nobody at FDA checks it for safety, effectiveness or quality before it is sold. Some use salt forms FDA calls different ingredients, and many come as vials dosed in units, not pens dosed in milligrams. Read the label's ingredient line and get your dose written in milligrams.

Every number checked at its primary source · · 10 sources · How we research

Evidence: Regulatory documents, not clinical trials: FDA statements dated July 2024 to October 2026, the Federal Register, FDA's drug shortage database and the FDA-approved labels.

A man in a navy quarter-zip carrying a tote of greens and a baguette down a brick street

What is a compounded drug?

Compounding is a pharmacist or doctor preparing a drug for a patient whose needs an approved product can't meet; FDA's own examples are a person allergic to a dye in the approved version, or a child who can't swallow a tablet3. The key fact for this question sits in one line of FDA's guidance: "Compounded drugs are not FDA-approved," so FDA does not verify their safety, effectiveness or quality before they are marketed3. Ozempic, Wegovy, Mounjaro and Zepbound went through that review; a compounded semaglutide or tirzepatide did not.

US law has two lanes for compounding. Under section 503A, a state-licensed pharmacy compounds for individual prescriptions and is overseen mainly by its state board of pharmacy; it does not have to follow current good manufacturing practice (CGMP), the factory quality rules drug makers follow3. Under section 503B, an outsourcing facility registers with FDA, follows CGMP and is inspected by FDA on a risk-based schedule3.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault keeps the draw you type for your current dose, in units, mL or pen clicks, shows it on the syringe size you choose, and says so when the units are more than that syringe holds. It records your numbers and works none of them out.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Why was compounded semaglutide and tirzepatide allowed, and when did that end?

Because the brands were in short supply. While a drug is on FDA's shortage list, compounders get more room to make copies of it. Once FDA declares the shortage resolved, it generally treats the brand as commercially available again, and it gave compounders a set number of days to stop1. Each date below is FDA's own.

DateDrugWhat FDA said
Oct 2, 2024TirzepatideThe shortage is resolved1.
Oct 22, 2024TirzepatideAfter a lawsuit, the removal from the shortage list was sent back to FDA to reevaluate1.
Dec 19, 2024TirzepatideReevaluated: the shortage is resolved. 503A pharmacies had until Feb 18, 2025 and 503B facilities until Mar 19, 20251.
Feb 21, 2025SemaglutideThe shortage is resolved. 503A pharmacies had until Apr 22, 2025 and 503B facilities until May 22, 20251.
Mar 10, 2025TirzepatideA court denied a request to block the decision on Mar 5, so the 503A period was over and the 503B period ran to Mar 19, 20251.
Apr 28, 2025SemaglutideA court denied the same kind of request on Apr 24, so the 503A period was over and the 503B period ran to May 22, 20251.
Apr 1, 2026BothNeither appears on the 503B bulks list or on FDA's drug shortage list1.
Apr 30, 2026BothFDA proposed to keep both off the 503B bulks list, finding no clinical need for outsourcing facilities to compound them5.
A timeline from October 2024 to November 2026: tirzepatide’s shortage resolved (reevaluated December 19, 2024), with 503A pharmacies ending February 18 and 503B facilities March 19, 2025; semaglutide’s resolved February 21, 2025, with 503A ending April 22 and 503B May 22, 2025; in April 2026 neither is on the 503B bulks list
Each drug got two deadlines after its shortage ended: pharmacies first, outsourcing facilities a month later.

The April 2026 proposal is not final. FDA extended its comment period to July 30, 20266, and the Federal Register showed no final decision on it when this guide was reviewed. As of November 20, 2026, FDA's drug shortage database lists no shortage of semaglutide injection or of tirzepatide7.

Can a pharmacy still compound them?

Only in narrow cases, as of FDA's April 1, 2026 statement1. An outsourcing facility (503B) may compound from bulk ingredient only what is on the 503B bulks list or the shortage list, and neither drug is on either1. A 503A pharmacy may not compound what FDA calls "essentially a copy" of an approved drug regularly or in large amounts: the same active ingredient at a similar strength, given the same way1.

Two limits sit inside that rule. A product is not a copy when a prescriber determines and documents that a change makes a significant difference for a named patient1. And adding a vitamin does not by itself change the answer: FDA's own example treats an injectable semaglutide with cyanocobalamin (vitamin B12) as a possible copy when both amounts are within 10% of approved products' strengths1. FDA also says it does not intend to act against a 503A pharmacy that fills four or fewer prescriptions of such a product in a calendar month1.

Is compounded semaglutide the same molecule as Ozempic?

Not always. The approved labels describe one exact molecule: semaglutide is a chain of amino acids with an 18-carbon fatty acid attached at position 26, which lets it bind albumin, a blood protein, and gives it its long half-life89. Tirzepatide carries a 20-carbon fatty acid for the same purpose10. FDA says some compounders sell semaglutide sodium or semaglutide acetate, salt forms that "are different active ingredients than are used in the approved drugs"2. FDA adds that it has no information on whether these salts behave the same in the body, and knows of no lawful basis for using them in compounding2.

Peptide SkySee Semaglutide as a molecule53 peptides as a night sky in 3D. Each star opens into its molecule, one bead per amino acid, with the measured shape where one exists.Open the Peptide Sky

Even when a pharmacy uses the same base molecule, no FDA review has checked that a given vial contains what its label says, in the amount it says, without contaminants3. FDA has also found fraudulent products labeled as compounded semaglutide or tirzepatide, some naming pharmacies that do not exist, and counterfeit Ozempic in the US supply2.

What else differs between a brand pen and a compounded vial?

WhatThe brand (per its FDA label)A compounded product (per FDA)
FDA reviewApproved; the label lists every ingredient by amount8910Not approved; not reviewed for safety, effectiveness or quality before sale3
Active ingredientSemaglutide or tirzepatide as described in the label810May be a salt form FDA calls a different active ingredient2
How a dose comesFixed doses in milligrams: single-dose pens, multi-dose pens, prefilled syringes, and for Zepbound single-dose and multi-dose vials8910Often a multiple-dose vial drawn up with a syringe; concentrations vary between products4
Other ingredientsListed in the label, such as phenol and propylene glycol in the Ozempic pen8May add ingredients such as cyanocobalamin1
HandlingStorage rules in the labelFDA has complaints of shipments arriving warm or with too little ice2
A pen whose dose window reads 0.25, in milligrams, beside a vial and a syringe with no mark set, labelled with the three units a vial user juggles: mg, mL and units
The pen speaks milligrams; a compounded vial leaves you to turn milligrams into a mark on the syringe, the step where most reports in FDA's July 2024 alert went wrong.

The device difference matters more than it looks. A brand pen delivers a dose fixed in milligrams. Zepbound's vials print the dose in milligrams and the volume that carries it: each single-dose vial holds one dose of 2.5 to 15 mg in 0.5 mL, and each multi-dose vial gives 4 doses of 0.6 mL10. A compounded vial leaves the person holding the syringe to turn milligrams into a volume, and most reports in FDA's July 2024 alert describe a problem at that step: patients drawing more than the prescribed dose from a multiple-dose vial4.

Why do dosing errors happen with compounded vials?

Because three units of measure meet on one syringe. In its July 2024 alert, FDA described patients drawing five to 20 times the intended dose of compounded semaglutide from multiple-dose vials, and clinicians who miscalculated when converting milligrams to units or milliliters, leading to five to 10 times the intended dose4. FDA named unfamiliarity with drawing from a vial and confusion between milliliters, milligrams and "units" as contributing causes4. The reported effects included nausea, vomiting, belly pain, fainting, headache, migraine and dehydration, and in some reports pancreatitis or gallstones; some people sought medical care or were admitted to hospital4.

FDA also has reports of compounded doses prescribed beyond the approved label: larger doses, more frequent dosing or faster step-ups2. FDA asks prescribers and compounders to give patients the right size of syringe and to show them how to measure the dose4. If you use a vial, these checks follow FDA's points in the order you meet them:

  1. Read the active ingredient on the label. If it says semaglutide sodium or semaglutide acetate, that is a salt form FDA knows no lawful basis to compound; raise it with your prescriber2.
  2. Find the strength on the vial label, in milligrams per milliliter, and keep it with the vial's record.
  3. Ask your prescriber or pharmacist to write your dose in milligrams and as the mark on your syringe, and check that the syringe you have is the size they meant4.
  4. Use a new sterile needle and syringe for each dose, and discard the vial 28 days after first use, even if some is left2.
  5. If a shipment arrives warm or without enough cold packs, do not use it; FDA advises against using any injectable GLP-1 that arrives that way2.

PepVault keeps the draw you type for your current dose, in units, mL or pen clicks, shows it on the syringe size you choose, and says so when the units are more than that syringe holds. It records your numbers and works none of them out. Log it in PepVault

When to get help If a dose may have been larger than intended, or vomiting or belly pain won't settle, call your prescriber or Poison Control the same day.

What has the FDA seen in adverse event reports?

As of May 31, 2026, FDA had received 990 reports of adverse events associated with compounded semaglutide and more than 730 with compounded tirzepatide2. Both counts are likely low, because federal law does not require state-licensed pharmacies to report adverse events to FDA, and a single report does not show that the drug caused the event2. In reports of doses beyond the approved label, the effects patients described were the familiar ones of the drug class: nausea, vomiting, diarrhea, belly pain and constipation2.

What does this mean if you are taking one now?

That the product in your hands is defined by its label, not by the brand it resembles. A compounded dose is not automatically the same as a brand dose of the same number, because the strength, the ingredient form and the measuring step can all differ. Whether to stay on a product, switch to an approved one or change a dose is a decision for you and your prescriber, made with the label in front of you both.

Commonly reported: people moving between a compounded vial and a brand pen say the hardest part is the language of the dose. Their vial instructions came in units or milliliters, the pen speaks only milligrams, and the two did not line up until a prescriber restated the dose in milligrams. Many also describe the pen as easier, with no syringe to fill.

Track it in the app

Sources

  1. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (dated entries Oct 2, 2024 to Apr 1, 2026; content current as of Apr 1, 2026). fda.gov
  2. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss (content current as of Oct 1, 2026). fda.gov
  3. U.S. Food and Drug Administration. Compounding and the FDA: questions and answers (content current as of Sep 16, 2025). fda.gov
  4. U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products (Jul 26, 2024). fda.gov
  5. U.S. Food and Drug Administration. FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list (Apr 30, 2026). fda.gov
  6. Federal Register 2026-12937. List of bulk drug substances for which there is a clinical need under section 503B; extension of comment period (Jun 26, 2026). federalregister.gov
  7. U.S. Food and Drug Administration. Drug shortages database (read Nov 20, 2026). accessdata.fda.gov
  8. Ozempic (semaglutide) injection. Prescribing information, Novo Nordisk, DailyMed SPL version 20 (effective Jun 1, 2026), section 11. dailymed.nlm.nih.gov
  9. Wegovy (semaglutide) injection and tablets. Prescribing information, Novo Nordisk, DailyMed SPL version 19 (effective Jun 18, 2026), section 11. dailymed.nlm.nih.gov
  10. Zepbound (tirzepatide) injection. Prescribing information, Eli Lilly, DailyMed SPL version 40 (effective Aug 28, 2026), sections 11 and 12.1. dailymed.nlm.nih.gov

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo